Company Overview and News
Thank you. Good afternoon everybody in Europe, good morning in the U.S. Welcome to our Q1 Business Update and Financial Results Call. It’s the second one since we are a dual listed company Euronext and Nasdaq, so I’d draw double attention on Slide 2 on the disclaimer. And then jump quickly to the agenda. So as usual I’ll start with a business update, Eric will take over with the financial results the highlights for Q1, and also we’ll take the news flow and the milestones and then we’ll come back to Q&A, we’ll open the floor for Q&A.
LYON, France, May 14, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced that it has appointed Alex Dusek as its Vice President Commercial Strategy and member of the executive team. Mr. Dusek brings 25 years of experience in market access, product marketing and sales across small biotech start-ups and multi-national pharmaceutical companies.
LYON, France, May 09, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its 2018 first quarter conference call and webcast on Tuesday, May 15, 2018, at 2:30 PM CEST/8:30 AM EST to discuss operational highlights.
LYON, France, 24 avr. 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP), société biopharmaceutique de stade clinique développant à partir de sa plateforme propriétaire d’encapsulation de médicaments dans les globules rouges des thérapies innovantes contre des formes sévères de cancers et des maladies orphelines, annonce avoir déposé auprès de l’Autorité des Marchés Financiers (AMF) en France son Document de Référence au titre de l′exercice clos le 31 décembre 2017 et son Form 20-F au titre de l′exercice clos le 31 décembre 2017 auprès de la « Securities and Exchange Commission » (SEC).
LYON, France, April 24, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP), the clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced that it had filed its 2017 “Document de Référence” for the year ended December 31, 2017, including the management report and the annual financial report with the “Autorité des Marchés Financiers (AMF)” and its Annual Report on Form 20-F for the year ended December 31, 2017 with the U.
Homology is looking at a new way to advance gene editing, but its treatments will require substantive time to go through FDA approval.
Small- and mid-cap biotech stocks have displayed usual first quarter resilience, setting the stage for second quarter upside.
The following slide deck was published by Erytech Pharma S.A. ADS in conjunction with this event.
The following slide deck was published by Erytech Pharma S.A. ADS in conjunction with their 2017 Q4 earnings call.
ERYTECH Pharma SA (OTC:EYRYY) Q4 2017 Results Earnings Conference Call March 13, 2018 8:30 AM ET
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
The JPMorgan Healthcare Conference is a significant event that readers interested in the sector should pay close attention to.
I revisit the bullish thesis below and remind readers of two upside driveres, ALL and pancreatic cancer.
Its unique technology platform ERYCAPS has allowed it to develop a promising pipeline of candidates developed by encapsulating therapeutic drug substances inside red blood cells.
Erytech Pharma (OTC:EYRYY) has 1 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 4,898,337 shares. Largest shareholders include Baker Brothers Advisors LP.
8h - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
8h - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
18h - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...